Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr. Reddy’s drug discovery operations in Hyderabad, India, will be integrated into Bangalore-based Aurigene, its wholly-owned independent subsidiary. The company is goint to shut the US–based Atlanta Research facility and form a new group that focuses on proprietary products development. Also, the company got approval for three of its Investigational New Drugs (INDs).
Subscribe to our email newsletter
Effective July 2009, Drug Discovery Research facility in Hyderabad will be known as Aurigene – Hyderabad. Thus, Aurigene will now operate from two locations: Bangalore and Hyderabad.
In collaboration with various partners and service providers, the new group will develop proprietary, branded R&D portfolio. The new unit, in association with Aurigene and other Discovery Biotechs, will manage the ongoing and future drug discovery programs. The group will own and manage existing intellectual property, and will be responsible for the development portfolio and the company’s differentiated formulations efforts.
Dr. Reddy’s said that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of atherosclerosis, dyslipidemia and associated cardiovascular diseases. The two other IND’s are meant for the treatment of dyslipidemia and COPD.